Can a patient with a modestly elevated ALT (less than 2 × upper limit of normal) and no symptoms of hepatitis safely start daily oral HIV pre‑exposure prophylaxis (tenofovir disoproxil fumarate + emtricitabine or tenofovir alafenamide + emtricitabine)?

Safety of Starting PrEP with Modestly Elevated ALT

Yes, a patient with modestly elevated ALT (less than 2× ULN) and no symptoms of hepatitis can safely start daily oral HIV pre-exposure prophylaxis with either TDF/FTC or TAF/FTC. The current guidelines do not list mild transaminase elevation as a contraindication to PrEP initiation, and baseline hepatitis B testing is recommended but should not delay PrEP start 1.

Pre-Initiation Requirements

Before starting PrEP in a patient with elevated ALT, the following baseline tests are recommended but should not impede PrEP initiation 1:

• HIV testing with combination antigen-antibody assay (mandatory to confirm HIV-negative status) 1, 2, 3
• Hepatitis B surface antigen (HBsAg) testing 1, 2, 3
• Hepatitis C antibody testing 2, 3
• Serum creatinine and estimated GFR (creatinine clearance must be ≥60 mL/min for TDF-based regimens) 1, 4, 3

The key point is that measurement of serum creatinine and HBsAg testing are recommended before initiation but need not impede PrEP initiation 1. This same principle applies to the modestly elevated ALT—it warrants investigation but should not delay starting PrEP in an otherwise appropriate candidate.

Monitoring Strategy for Elevated Transaminases

For patients with baseline elevated ALT on PrEP, implement the following monitoring approach:

• More frequent HCV serologic testing should be performed in patients with elevated transaminase levels (beyond the standard annual testing) 1
• Standard 3-month follow-up visits for HIV testing and STI screening remain mandatory 1, 2, 4
• Assess for hepatitis symptoms at each visit (severe fatigue, abdominal pain, nausea, vomiting) 5
• Repeat transaminase levels at the 1-month follow-up visit and then at least every 3-6 months 1

Critical Hepatitis B Considerations

The most important safety concern with modestly elevated ALT is undiagnosed chronic hepatitis B infection 1:

• If the patient has active HBV infection (detectable HBsAg), TDF/FTC or TAF/FTC can still be safely initiated and may actually benefit the patient by treating both HIV prevention and HBV 1
• Critical warning: Discontinuation of TDF/emtricitabine PrEP in patients with active HBV could lead to acute HBV flares or hepatic decompensation, particularly in those with hepatic cirrhosis 1
• Careful monitoring of HBV infection and liver function is required after discontinuation if HBsAg-positive 1

Regimen Selection with Elevated ALT

Both approved PrEP regimens are safe to initiate:

• TDF/emtricitabine (Truvada) is the first-line option for all populations at risk 1, 2, 4, 6
• TAF/emtricitabine (Descovy) is an alternative for MSM and transgender women (not approved for cisgender women at risk through vaginal exposure) 4, 7, 8
• TAF/FTC has demonstrated improved bone and renal safety biomarkers compared to TDF/FTC, with non-inferior HIV prevention efficacy 7, 8

Neither regimen is contraindicated by modest ALT elevation alone. The primary contraindications are creatinine clearance <60 mL/min for TDF-based regimens (or <30 mL/min for TAF-based regimens) and positive or unknown HIV status 1, 3.

Common Pitfalls to Avoid

Do not delay PrEP initiation while waiting for complete hepatitis workup in an asymptomatic patient with ALT <2× ULN 1. The risk of HIV acquisition during the delay likely outweighs the minimal risk from starting PrEP with modest transaminase elevation.

Do not confuse baseline ALT elevation with drug-induced liver injury (DILI) during PrEP. In clinical trials of both TDF/FTC and TAF/FTC for PrEP, ALT elevations were common (11-13% had grade 3-4 ALT elevations) but were not attributed to the study drugs 9. Most elevations in PrEP users reflect underlying viral hepatitis, alcohol use, or metabolic liver disease 1.

Do not discontinue PrEP abruptly if HBsAg testing returns positive after initiation, as this creates risk of hepatitis flare 1. Instead, continue the regimen and manage as dual HIV prevention/HBV treatment.

Algorithm for Clinical Decision-Making

1. Confirm HIV-negative status with combination antigen-antibody assay 1, 2, 3
2. Check creatinine clearance (must be ≥60 mL/min for TDF-based PrEP) 1, 4, 3
3. Order HBsAg and HCV antibody but do not wait for results if patient is asymptomatic 1, 2
4. Initiate PrEP same-day if HIV-negative and creatinine clearance adequate 1
5. Schedule 1-month follow-up to review hepatitis results, assess adherence, repeat HIV testing, and check transaminases 1
6. If HBsAg positive: Continue PrEP indefinitely (now treating both HIV prevention and HBV), counsel about flare risk with discontinuation 1
7. If HCV positive: Continue PrEP, refer for HCV treatment, monitor transaminases more frequently 1